When Will Weed Stocks Rise Again

When information technology comes to cannabis stocks, what tin get lost in the "weeds," so to speak, is the gains that these names have provided on a year-to-date (YTD) ground. Yes, the sector has roughly halved from its February peak. However, many long-term investors that haven't touched their weed stocks since the beginning of the year still have paper gains on the books at the fourth dimension of writing.

Many of the publicly traded cannabis players available to investors right now happen to be domiciled in Canada. And, due to the various banking and list restrictions in the The states, they are prohibited from selling THC products in the U.Southward. market place.

But the rate of growth n of the border is something cannabis investors volition want to watch closely. The Canadian market isn't 1 that typically gets a lot of attention. Still, when it comes to weed stocks, information technology's where a lot of the action is right now.

Canada reported some pretty impressive growth in legal cannabis sales last twelvemonth. Revenues from legal sales grew 120% over 2019 to $2.1 billion. Additionally, legal sales surpassed "illicit" sales for the get-go time in the country'due south history. Nine out of Canada'southward ten provinces saw growth.

As the first major economic system to legalize cannabis for recreational purposes, the Canadian growth trajectory in this manufacture will probable be looked to equally a fundamental indicator for how other major economies perform post-legalization. So, for those honing in on the Canadian market place today, here are seven weed stocks to proceed an eye on right now:

• Canopy Growth(NASDAQ: CGC )
• Tilray (NASDAQ: TLRY )
• Aphria(NASDAQ: APHA )
• Aurora Cannabis(NYSE: ACB )
• Hexo(NYSE: HEXO )
• Cronos(NASDAQ: CRON )
• Organigram(NASDAQ: OGI )

Weed Stocks to Buy: Canopy Growth (CGC)

Source: Shutterstock

With a market capitalization of more than $10 billion, Canopy Growth is a formidable player in the Canadian cannabis space. In fact, it's been the forerunner in this sector for some time.

Aye, the combined Tilray-Aphria will be larger upon completion. For now, though, CGC stock is the bellwether proper name that virtually investors look to when they recall most the Canadian weed stocks.

Formerly known equally Tweed, this company has built a significant market share in Canada across both recreational and medical cannabis. CGC's core products and brands take spurred large investment involvement non only in Canada, simply from the U.S. likewise. Investors may too think that beer maker Constellation Brands(NYSE: STZ ) took a large pale in Canopy in contempo years. The company effectively owns roughly 40% of Canopy after exercising warrants terminal year.

In addition to its Canadian business, all the same, Canopy too acquired Acreage Holdings in a deal which was repriced to $843 million, down from the original price of $3.four billion in 2019.

Investors are hopeful this Acreage bargain will result in a drinkable line being rolled out in the U.Southward. in the summer of 2021. Given Acreage's U.S. exposure, investors have something to be excited most with CGC, especially with the contempo speculation effectually U.South. federal legalization of belatedly.

Tilray (TLRY)

Source: Jarretera / Shutterstock.com

Okay, now on to that Tilray-Aphria deal I merely mentioned. The combined firm volition be the largest in Canada — and the earth for that matter — upon completion. Additionally, this deal looks closer than ever to existence approved. This month, Aphria shareholders voted in favor of the combination.

Then, it seems this company is full-steam alee on its combination efforts. The deal is expected to close sometime in the 2nd quarter of this year. Of course, regulators withal demand to approve the deal in Canada, the U.Due south. and Germany. However, all indications are this combo is likely to happen.

At present, U.S. multi-state operators (MSOs) are growing fast, then I'd expect this global leadership to eventually be eclipsed at some point. For now, though, TLRY stock is the pre-eminent name that many cannabis investors are watching right now.

Tilray's market cap of around $3 billion previously placed this company as a top-tier player in the space, admitting smaller than Aphria (which has a market cap of $4.half-dozen billion today). Now, it's expected that Aphria stakeholders will own roughly 62% of outstanding Tilray shares upon completion.

Lately, TLRY has been one of investors' favorite weed stocks. Shares were bid upwardly to as high as $67 post-obit the recent meme-stock mania earlier this year. Right now, though, investors can pick up shares of the stock for simply under $18 apiece.

Given the pending merger and the aggressive cost-savings targets associated with the deal, investors may exist getting a steal with Tilray today.

Weed Stocks to Buy: Aphria (APHA)

Source: Jetacom Autofocus / Shutterstock.com

Now, as the visitor that is likely to come up out the winner in this mega-merger, Aphria shareholders may have more to like about the deal.

Afterward all, they'll own the bulk of shares of the combined entity. And, the company's move into the U.S. via its conquering of Sweetwater Brewing for $300 million belatedly terminal year positions Aphria well to take advantage of the growth in the U.S. "cannabis 2.0" products segment.

Indeed, one of the key profitability drivers for cannabis producers over the long-booty will be the ability to increase margins over fourth dimension with new products. These two.0 products include CBD-infused beverages, oils, vapes and other value-added products with college margins.

Cannabis is a commodity — just similar corn, wheat or soy beans. Long-term, cannabis producers will be price-takers, with little ability to increase their margins over fourth dimension outside of value-added activities within the processing of these raw materials and other vertical-integration beyond the supply chain.

In this sense, APHA stock appears to exist well-positioned over other weed stocks. I like the company's existing verticals. Additionally, I think the value added from its deal with Tilray should create scale. This scale should provide investors with a larger moat over the long haul. That'south a great thing.

Aurora Cannabis (ACB)

Source: Shutterstock

Recently, Aurora Cannabis has been nether pressure. Shares have traded relatively apartment over the by yr and are merely slightly up on a YTD basis. Using the company'south 52-week high of $19.68, ACB stock is down more than 55% from its meridian.

Now, this is generally in line with the broader sector. Notwithstanding, Aurora'southward stock has been slightly more volatile than other weed stocks. I think a significant reason for this is the company's focus on premium cannabis production lines spanning both the medical and recreational spaces. However, investors seeking higher margin growth may be enticed to take a look at Aurora equally a winner in this segment of the market.

According to Aurora's website, the company remains focused on "state-of-the-fine art facility applied science, cannabis breeding, research, and industry-leading product development, creating brands that suspension through wherever they are launched." Additionally, Aurora has entered the U.S. CBD marketplace through its Reliva brand.

Like its peers, Aurora is attempting to position itself as a key histrion in the U.Southward. cannabis marketplace prior to legalization. How this translates into the THC market remains to be seen. Withal, information technology appears at that place'southward some unique upside to ACB stock that analysts like correct now.

Weed Stocks to Purchase: Hexo (HEXO)

Source: Shutterstock

HEXO stock is one of those diversified Canadian weed stocks that long-term investors will want to focus on.

Why? For starters, Hexo has potent domestic product, peculiarly in its home province of Quebec. The company'south multi-year distribution contract is something many investors focus on, especially because Quebec has a way of treating dwelling house-grown companies better than other provinces. And so, from a domestic standpoint, Hexo has found a bang-up regional niche market to dominate.

Importantly, though, Hexo has besides actually made decent headway in growing its international portfolio. For example, the company has been making deals in Israel and Europe, bolstering its footprint outside of Canada. Farther, like its Canadian peers, Hexo is currently pretty much on the sidelines when it comes to the U.S. markets. However, its international deals should offer solid upside for investors seeking cannabis players with geographic diversification today.

In my view, though, the existent investment thesis for Hexo correct now is its beverage segmentation. The company'south partnership withMolson Coors(NYSE: TAP ) has tons of potential over the long term. Launching CBD-infused beverage lines in the U.S. volition go along to grow Hexo'southward market share in the cannabis-infused beverage marketplace.

Cronos (CRON)

Source: Shutterstock

One of the few weed stocks that'south still up on a YTD basis, investors in CRON stock are still showing paper gains of roughly xx% at the fourth dimension of this writing. That isn't at all bad because how far and fast this sector has fallen since Feb.

Cronos' CBD portfolio is what has enticed many investors to consider the company lately. However, this cannabis player is looking to continue the expansion of its value-added product portfolio likewise. For investors seeking higher-margin growth, this is a good thing. Among the products Cronos has continued to focus on are oils, vapes and other CBD-infused products. These offerings are, of course, complimentary to the company's dried bloom business in Canada.

Like to Organigram (which I'll get to in a minute), Cronos has also received an investment from a big tobacco player. Altria (NYSE: MO ) invested a massive sum in CRON dorsum in 2019. This investment appears to exist under water right at present, simply long-term investors may like the fact that Cronos has such strong backers today.

Additionally, Cronos is one of the few cannabis players with a decently stable balance sail. Unlike many of its peers, this name's outstanding debt is essentially zero. Other than capital leases and some current and non-electric current liabilities, Cronos' remainder sheet is about as make clean as they come up. Plus, strong earnings performance has prepare this company apart from its peers. So, long-term investors may want to consider CRON stock closely from a growth perspective.

Weed Stocks to Buy: Organigram (OGI)

Source: Shutterstock

The concluding entry on this list of weed stocks is a relatively modest-cap cannabis play that I've come to like: Organigram. At the time of writing, OGI has a market cap hovering around $800 million. That'due south pretty tiny in the thousand scheme of things. Still, I retrieve there are reasons investors should consider OGI stock today.

One key reason I'd advise investors look at Organigram is its backers. Recently,British American Tobacco(NYSE: BTI ) bought a 20% equity pale in Organigram. The cigarette industry has been looking more and more at shifting into cannabis. And then, for investors bullish on the value such partnerships could create, Organigram is an intriguing selection.

But some other fundamental reason that Organigram is on my radar today is its bargain to larn soft chew manufacturerEdibles & Infusions for a full of $35 meg, contingent on certain milestones existence hitting. Like I've said before, edibles and other value-added products will exist key profitability drivers for this sector. As such, OGI's move into this infinite is one small deal with large potential impact.

Of grade, OGI stock isn't without risk, as evidenced by the visitor'south share price movements in recent years. That said, for investors seeking a stock with high leverage to the growth that cannabis provides, this is it.

On the date of publication, Chris MacDonald did not accept (either straight or indirectly) whatever positions in the securities mentioned in this article.

Chris MacDonald's love for investing led him to pursue an MBA in Finance and take on a number of management roles in corporate finance and venture capital letter over the past 15 years. His feel as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

nicholssicke1945.blogspot.com

Source: https://investorplace.com/2021/04/seven-weed-stocks-buy-canada-consumption-continues-to-rise/

Share this post